Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170085 | 0.93 | CYP3A4 (0.83) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL31706363 | 0.92 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5257853 | 0.91 | CYP3A4 (0.63) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4180262 | 0.90 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1816215 | 0.90 | CYP3A4 (0.86) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5258282 | 0.89 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL14290065 | 0.89 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5257152 | 0.89 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6349099 | 0.88 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL2368041 | 0.86 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215593-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN | HETERO LABS LIMITED (IN) | 2025-10-16 | — | — | WO | claimed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | claimed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | claimed |
| EP-1105391-B1 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for thier preparation | ASTRAZENECA AB (SE) | 2004-10-27 | — | — | EP | claimed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | claimed |
| WO-2025215593-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ZASTAPRAZAN | HETERO LABS LIMITED (IN) | 2025-10-16 | — | — | WO | disclosed |
| EP-4563577-A1 | NOVEL SALT OF IMIDAZO[1,2-A]PYRIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND PREPARATION METHOD | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-06-04 | — | — | EP | disclosed |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| US-7691875-B2 | Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-7691875-B2 | Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-7691875-B2 | Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20070066642-A1 | Novel imidazopyridine compound ii with therapeutic effect | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| EP-1641793-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | AstraZeneca AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004113340-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND III WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113339-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113338-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND I WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066642-A1 | Novel imidazopyridine compound ii with therapeutic effect | GIPR, HRH2, VIP | CYP3A4 1521/4885CYP2C9 3408/4885CYP2D6 2510/4885 |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | HRH2, GIPR, HRH4 | CYP3A4 145/4885CYP2C9 477/4885CYP2D6 327/4885 |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | GIPR, PGC, VIP | CYP3A4 987/4885CYP2C9 1375/4885CYP2D6 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.